Phase III Study of S-877503 in Adult Patients with ADHD -long term extension study-

Phase III Study of S-877503 in Adult Patients with Attention-deficit/Hyperactivity Disorder -long term extension study-

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223177

Enrollment

190

Registered

2016-04-21

Start date

2016-12-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention-deficit/hyperactivity disorder

Interventions

investigational material(s) Generic name etc : S-877503 INN of investigational material : guanfacine Therapeutic category code : 117 Psychotropic agents Dosage and Administration for Investigational m

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient has completed 12-week administration in the preceding study of S-877503 in adult with ADHD, etc.

Exclusion criteria

Exclusion criteria: Patient has complications such as serious hepatic disorder, renal disorder, heart disease, lung disease, hematological disease, and metabolic disease. Patient has suicidal tendency. etc.

Design outcomes

Primary

Measure	Time frame
safety Percentage of patients with any adverse events, etc.	—

Secondary

Measure	Time frame
efficacy ADHD-RS IV with adult prompts (Japanese version), etc.	—

Countries

Japan

Contacts

Public ContactContact for Clinical Trial Information

Takeda Pharmaceutical Company Limited

smb.Japanclinicalstudydisclosure@takeda.com+81-6-6204-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026